Market research
ICY.F Incyte Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21B
- P/E ratio
- 15.65
- Analyst target
- 101.27
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45337C1027
- Market cap
- 21B
- P/E ratio
- 15.65
- Analyst target
- 101.27
- Dividend yield
- Not available
- Beta
- 0.77
About
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ICY.F discussion.
5 years, 5 months ago
Incyte Corporation is currently in a long term downtrend where the price is trading 1.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
Incyte Corporation's total revenue rose by 36.3% to $790M since the same quarter in the previous year.
Its net income has increased by 35.0% to $150M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.4% to $56M since the same quarter in the previous year.
Based on the above factors, Incyte Corporation gets an overall score of 3/5.